Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phospholipids as cardiovascular therapeutics.

Nihar R Pandey1, Daniel L Sparks

  • 1Liponex Inc, Ottawa, Ontario K1Y 4W7, Canada.

Current Opinion in Investigational Drugs (London, England : 2000)
|March 4, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondria: the indispensable players in innate immunity and guardians of the inflammatory response.

Journal of cell communication and signaling·2019
Same author

IRF2BP2 Reduces Macrophage Inflammation and Susceptibility to Atherosclerosis.

Circulation research·2015
Same author

Chronic stress induces anxiety via an amygdalar intracellular cascade that impairs endocannabinoid signaling.

Neuron·2015
Same author

Cross talk between Leishmania donovani CpG DNA and Toll-like receptor 9: an immunoinformatics approach.

Biochemical and biophysical research communications·2015
Same author

Functional properties of Claramine: a novel PTP1B inhibitor and insulin-mimetic compound.

Biochemical and biophysical research communications·2015
Same author

P2X receptors regulate adenosine diphosphate release from hepatic cells.

Purinergic signalling·2014
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Soy phosphatidylinositol (PI), a novel therapeutic, shows promise for heart disease prevention. Clinical trials indicate it is safe and effectively improves cholesterol and triglyceride levels by stimulating HDL production.

Area of Science:

  • Cardiovascular Medicine
  • Lipid Metabolism
  • Nutritional Biochemistry

Background:

  • Cardiovascular disease remains a leading cause of mortality worldwide.
  • Current therapies for dyslipidemia have limitations and side effects.
  • Novel therapeutic targets for heart disease prevention are needed.

Purpose of the Study:

  • To evaluate the safety and efficacy of soy phosphatidylinositol (PI) for cardiovascular disease treatment and prevention.
  • To investigate the mechanisms by which soy PI impacts lipid profiles.
  • To explore the potential of soy-derived phospholipids as a novel therapeutic strategy.

Main Methods:

  • Completed three Phase I and one Phase I/II clinical trials.
  • Assessed safety and tolerability at doses up to 5g.

Related Experiment Videos

  • Measured changes in plasma HDL-cholesterol, apolipoprotein A-I, and triglyceride levels.
  • Investigated the role of linoleic acid and MAPK signaling in PI's mechanism of action.

    • Main Results:

    • Soy PI demonstrated a favorable safety profile across all completed trials.
    • Early-stage efficacy suggests PI can increase HDL-cholesterol and apolipoprotein A-I.
    • PI treatment led to a reduction in triglyceride levels in human subjects.
    • Linoleic acid in soy PI is crucial for PPAR-alpha dependent HDL secretion.

    Conclusions:

    • Soy phosphatidylinositol (PI) is a safe and potentially efficacious therapeutic for cardiovascular disease.
    • PI modulates lipid metabolism through mechanisms involving MAPK and PPAR-alpha signaling.
    • Soy-derived phospholipids represent a novel therapeutic opportunity for managing dyslipidemia and preventing heart disease.